Disclosure Statement

Disclosure Statement

Task Force disclosure information is provided for the two years prior to March 2008 and the known future as of February 2009. RTK served as a consultant for AstraZeneca, Bayer Pharmaceuticals Corporation, and Onyx Pharmaceuticals, Inc. (without compensation), and received grant support from Exelixis and Eisai. GLF is a stockholder of Pfizer Inc. RFG served as a consultant for Exelixis, and received grant support from AstraZeneca. MDR served as a consultant for Amgen, and received grant support from Exelixis and Eisai. MS served as a consultant for AstraZeneca; received speaker honoraria from AstraZeneca and Pfizer Inc.; and received or is the potential recipient of grant support from AstraZeneca, Amgen, Exelixis, and Eisai. SAW received speaker honoraria from AstraZeneca. CE, DBE, HG, JFM, and FP report that no competing financial interests exist.